TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06721923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein
Description: Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
Study: NCT06719973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: Participants will receive an escalating doses of M9466 orally in 21-day cycles until disease progression, intolerable toxicity, death, withdrawal of study or study consent, lost to follow-up, or end of study.
Study: NCT06050382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROGRESSIVE RELAXATION TRAINING
Description: Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROGRESSIVE RELAXATION TRAINING
Description: Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling.
Study: NCT06719973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9446
Description: M9446 dose will be further investigated in Module 2 Part A of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9446
Description: M9446 recommended Dose for Expansion (RDE) will be further investigated in Module 2 Part B of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously as per standard of care.
Study: NCT06720519

Intervention type: DIAGNOSTIC_TEST
Intervention: QIAstat-Dx®Meningitis/Encephalite Panel
Description: The analytical sensitivity of the test is assessed by comparing the results obtained with those known from routine diagnostic tests.~For viruses only, the semi-quantitative value of Ct is also evaluated with the viral load provided by qPCR.
Study: NCT06721832

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spina plane block (ESP)
Description: The block will be performed in prone position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) T1 transverse process will be approached with an 18 G Tuohy's needle in caudal-to-cranial direction. A total of 30 ml of 0.25% bupivacaine with 150 μg of clonidine and 8 mg dexamethasone was administered deep to erector spinae muscle (ESM) bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block (ESP)
Description: The block will be performed in prone position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) T1 transverse process will be approached with an 18 G Tuohy's needle in caudal-to-cranial direction. A total of 30 ml of 0.25% bupivacaine with 150 μg of clonidine and 8 mg dexamethasone was administered deep to erector spinae muscle (ESM) bilaterally.
Study: NCT06720181

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain
Study: NCT06720324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
Study: NCT06721494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methamphetamine
Description: Methamphetamine HCl for intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: Methamphetamine HCl for intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Sterile Saline for intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS-1103
Description: CS-1103 for intravenous administration
Study: NCT06721897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: A prehabilitation programme supervised by a physiotherapist in a ward is proposed, with a frequency of 3 sessions/week on alternate days lasting 30-45 min/session, in addition to a daily physical exercise programme at home.~The programme will consist of a warm-up, strength exercises with progressive loads, proprioception, balance, cardiovascular training aimed at functional work and a cool-down.~The home programme will be complementary to the supervised programme, which will consist of daily sessions of 20-30 min of flexibility and proprioception exercises.~The same prehabilitation protocol will be proposed for those patients awaiting total hip and knee replacement surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non prehabilitation Program
Description: The control group (CG) will carry out a post-operative physiotherapy program in addition to a home exercise program that will be shown by the physiotherapist before hospital discharge.
Study: NCT06720337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Description: patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Description: patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique
Study: NCT06367959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Esays
Description: Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Esays
Description: Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay.
Study: NCT04899570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
Study: NCT06720337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: patients will receive plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
Study: NCT05820451

Intervention type: DEVICE
Intervention: Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution
Description: US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.

Intervention type: DEVICE
Intervention: Impella RP with Sodium Bicarbonate used as purge solution
Description: US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
Study: NCT05545072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
Study: NCT04899570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
Study: NCT05545072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Corticosteroid Sprays (INCS)
Description: All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will be continued throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Corticosteroid Sprays (INCS)
Description: All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will be continued throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
Study: NCT04899570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
Study: NCT06147141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Peer Companion Intervention
Description: Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
Study: NCT06353581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulapeg
Description: Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
Study: NCT05751824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS)
Description: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manually remind the patients to review.
Description: Medical staff remind patients to review by telephone.
Study: NCT05422105

Intervention type: DRUG
Intervention: 18F-PSMA-1007
Description: 18F-PSMA-1007 PET/CT
Study: NCT06648408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balett Training
Description: The ballet training will happen twice a week for six weeks, with each session lasting 60 minutes, for a total of 12 sessions. These sessions will be held in groups of 10 to 12 children and led by experienced ballet teachers. The classes will follow a beginner-level ballet routine, introducing the kids to ballet techniques in a fun and playful way, making sure they learn the movements step by step. Each lesson will follow the same structure, allowing the children to improve their skills week after week. In addition to the group sessions, the children will be given a 10-minute daily home exercise program. This will include simple ballet exercises they learned in their first class, which they should practice on the five days when they don't have ballet sessions. The children will track their practice in a child-friendly diary designed just for them.
Study: NCT06653491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure
Description: high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simulated ankle technique
Description: simulated ankle technique in a supine position
Study: NCT05082922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid treatment
Description: Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
Study: NCT05910268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx + ECHO
Description: Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx + ECHO
Description: Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx + ECHO
Description: Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
Study: NCT06240468

Intervention type: OTHER
Intervention: not have
Description: not have

Intervention type: OTHER
Intervention: not have
Description: not have

Intervention type: OTHER
Intervention: not have
Description: not have
Study: NCT06418789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )
Description: TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested.
Study: NCT06147141

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-List
Description: Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
Study: NCT05189119

Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive ventilation
Description: invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5

Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive ventilation
Description: invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
Study: NCT06527781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD5K3
Description: Six dose levels will be evaluated. intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Six dose levels will be evaluated. intramuscular injection
Study: NCT05252949

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oleoylethanolamide (OEA)
Description: Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.